HC Wainwright Reaffirms “Buy” Rating for GH Research (NASDAQ:GHRS)

GH Research (NASDAQ:GHRSGet Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued on Friday,Benzinga reports. They currently have a $40.00 target price on the stock. HC Wainwright’s price objective indicates a potential upside of 366.74% from the company’s previous close.

Separately, Canaccord Genuity Group cut their price objective on shares of GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a research report on Monday, November 18th.

Check Out Our Latest Report on GH Research

GH Research Price Performance

Shares of NASDAQ GHRS opened at $8.57 on Friday. The firm has a market capitalization of $445.88 million, a PE ratio of -10.85 and a beta of 0.84. GH Research has a 1-year low of $5.50 and a 1-year high of $14.99. The business’s fifty day moving average price is $8.44 and its two-hundred day moving average price is $9.19.

Institutional Trading of GH Research

A hedge fund recently raised its stake in GH Research stock. Lynx1 Capital Management LP lifted its holdings in GH Research PLC (NASDAQ:GHRSFree Report) by 19.8% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,966,726 shares of the company’s stock after purchasing an additional 656,163 shares during the quarter. GH Research accounts for approximately 16.7% of Lynx1 Capital Management LP’s holdings, making the stock its 3rd largest position. Lynx1 Capital Management LP owned approximately 7.62% of GH Research worth $46,252,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 56.90% of the company’s stock.

GH Research Company Profile

(Get Free Report)

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

Featured Articles

Receive News & Ratings for GH Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GH Research and related companies with MarketBeat.com's FREE daily email newsletter.